Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease
- PMID: 7859802
- DOI: 10.1007/BF00194965
Characteristics of plasma protein binding of tacrine hydrochloride: a new drug for Alzheimer's disease
Abstract
The aim of this study was to characterise the plasma protein binding of tacrine hydrochloride (THA) in vitro. Binding was assessed in the plasma of 11 healthy individuals aged 20 to 27 years using ultrafiltration followed by HPLC assay. At THA concentrations from 10 to 100 ng/ml protein binding ranged from 78.6 to 71.0%. Binding to commercially available human albumin ranged from 41.7 to 38.3% and to human alpha 1-acid glycoprotein from 23.1 to 12.4% over the THA concentrations from 25 to 100 ng/ml. THA binding and total plasma protein, plasma albumin and alpha 1-acid glycoprotein were measured in healthy young subjects (n = 13), healthy elderly individuals (n = 12) and patients hospitalised with acute illnesses (n = 8). There were significant differences between the groups in total plasma protein, plasma albumin and in alpha 1-acid glycoprotein but no differences in the protein binding of THA which remained constant at about 75%. There was no correlation between THA binding and any plasma protein concentration. The THA binding was not high enough to be of major significance clinically or to reduce the validity of total plasma THA measurement in therapeutic monitoring.
Similar articles
-
Variability in the plasma protein binding of velnacrine (1-hydroxy tacrine hydrochloride). A potential agent for Alzheimer's disease.Eur J Clin Pharmacol. 1996;50(1-2):115-9. doi: 10.1007/s002280050078. Eur J Clin Pharmacol. 1996. PMID: 8739821 Clinical Trial.
-
Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease.Clin Pharmacol Ther. 1993 Jun;53(6):691-5. doi: 10.1038/clpt.1993.91. Clin Pharmacol Ther. 1993. PMID: 8513661 Clinical Trial.
-
Tacrine treatment of Alzheimer's disease: many expectations, few certainties.Neuropsychobiology. 1998 Nov;38(4):226-31. doi: 10.1159/000026546. Neuropsychobiology. 1998. PMID: 9813462
-
[Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS].Therapie. 1992 May-Jun;47(3):245-7. Therapie. 1992. PMID: 1295125 Review. French.
-
Tacrine in the treatment of Alzheimer's disease. A clinical update and recent pharmacologic studies.Eur Neurol. 1989;29 Suppl 3:28-32. doi: 10.1159/000116478. Eur Neurol. 1989. PMID: 2693104 Review.
Cited by
-
Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery.Pharm Res. 2014 Aug;31(8):2107-23. doi: 10.1007/s11095-014-1312-8. Epub 2014 Feb 20. Pharm Res. 2014. PMID: 24554118
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical